Cargando…
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
OBJECTIVES: Treatment patterns for patients with myelodysplastic syndromes (MDS) outside clinical trials are not well described. Our objective was to evaluate treatment patterns and patient characteristics that influence time to disease-modifying therapy in patients with MDS in the USA. DESIGN, PART...
Autores principales: | Ma, Xiaomei, Steensma, David P, Scott, Bart L, Kiselev, Pavel, Sugrue, Mary M, Swern, Arlene S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059277/ https://www.ncbi.nlm.nih.gov/pubmed/30037860 http://dx.doi.org/10.1136/bmjopen-2017-019955 |
Ejemplares similares
-
Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash
por: Weiss, Lilia, et al.
Publicado: (2015) -
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
por: Steensma, David P., et al.
Publicado: (2016) -
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018) -
Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes
por: Chen, Qiuni, et al.
Publicado: (2022) -
Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes
por: Patel, Jay L., et al.
Publicado: (2020)